|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0014921,
umls-concept:C0021747,
umls-concept:C0022265,
umls-concept:C0026259,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0036525,
umls-concept:C0078257,
umls-concept:C0144576,
umls-concept:C0282460,
umls-concept:C0376358,
umls-concept:C0376515,
umls-concept:C1522484,
umls-concept:C1709059
|
|
pubmed:dateCreated |
2010-3-15
|
|
pubmed:abstractText |
To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC).
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178647-10561278,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178647-11525294,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178647-11956165,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178647-12768320,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178647-12796360,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178647-1458483,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178647-15470214,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178647-15838657,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178647-16098366,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178647-17476141,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178647-18084610,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178647-18287387,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178647-18599488,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178647-19087985,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178647-19737977,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178647-2691207
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1479-5876
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
20
|
|
pubmed:dateRevised |
2010-9-30
|
|
pubmed:meshHeading |
pubmed-meshheading:20178647-Aged,
pubmed-meshheading:20178647-Aged, 80 and over,
pubmed-meshheading:20178647-Antineoplastic Agents,
pubmed-meshheading:20178647-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20178647-Estramustine,
pubmed-meshheading:20178647-Humans,
pubmed-meshheading:20178647-Interferons,
pubmed-meshheading:20178647-Isotretinoin,
pubmed-meshheading:20178647-Male,
pubmed-meshheading:20178647-Middle Aged,
pubmed-meshheading:20178647-Mitoxantrone,
pubmed-meshheading:20178647-Neoplasm Metastasis,
pubmed-meshheading:20178647-Paclitaxel,
pubmed-meshheading:20178647-Prostatic Neoplasms,
pubmed-meshheading:20178647-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:20178647-Quality of Life,
pubmed-meshheading:20178647-Survival Rate,
pubmed-meshheading:20178647-Teratogens,
pubmed-meshheading:20178647-Treatment Outcome,
pubmed-meshheading:20178647-Vinblastine
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.
|
|
pubmed:affiliation |
Department of Medicine, The Cancer Institute of New Jersey, UMDNJ-RWJMS, New Brunswick NJ, USA. dipaolrs@umdnj.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Clinical Trial, Phase II
|
